(AOF) – Median Technologies announces that the first results of its iBiopsy HCC detection AI model will be presented at the annual congress of ESMO (European Society for Medical Oncology), which will be held from October 20 to 24 in Madrid. The medtech specifies that the main objective of the study was to evaluate the iBiopsy AI model for the detection of hepatocellular carcinoma (HCC – Hepatocellular Carcinoma (HCC)), with the ultimate goal of targeting the early diagnosis of this type primary liver cancer.
The medtech specifies that Median’s iBiopsy HCC AI model was designed to detect liver lesions from 1 cm in diameter, and that it showed promising results, with a detection sensitivity of 92% on the game of test data, a result much higher than the detection sensitivity of 69% observed on average in a population of radiologists who do not have detection assistance software integrating AI. According to the company, the next stages of study will focus on small liver lesions to improve the diagnosis of HCC at very early (0) and early (A) stages.
© 2023 Agence Option Finance (AOF) – All reproduction rights reserved by AOF. AOF collects its data from the sources it considers the safest. However, the reader remains solely responsible for their interpretation and use of the information made available to them. The reader must therefore hold AOF and its contributors harmless from any claim resulting from this use. Agence Option Finance (AOF) is a brand of the Option Finance group
Did you like this article ? Share it with your friends using the buttons below.
